Stevan Djuric

Dr Stevan Djuric is head of the global Abbott Medicinal Chemistry Leadership Team at Abbott and is also responsible for the Medicinal Chemistry Technology and Structural Chemistry groups within their Discovery organization and chemistry outsourcing activities. The group's current efforts are focused on new initiatives in the areas of high throughput synthesis and purification, hit to lead chemistry, chemical biology including target identification proteomics and new enabling technology identification and development.

During his tenure at Abbott Laboratories, Dr Djuric has been a Project Leader for groups in the Immunoscience, Metabolic Disease, and Antiinfective areas. Several of these programs have advanced compounds into clinical development and to the market including Abbott's proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe.

Dr Djuric has over 150 scientific publications, presentations and patents/applications pending. He has also given over 30 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards and, in addition, holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas.